ArticleBMC microbiology2026
Phenotypic-genotypic characteristics of Corynebacterium striatum clinical isolates and diversified biofilm production capabilities in the presence of plasma proteins.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCorynebacterium striatum is an opportunistic pathogen associated with a wide range of hospital-acquired infections, in which biofilm production plays a critical role in nosocomial transmission and pathogenicity. Although genotypic heterogeneity among C. striatum clinical isolates has been increasingly recognized, factors influencing isolate-specific biofilm formation, particularly host-derived factors, remain poorly understood. This study investigated the biofilm formation characteristics of C. striatum isolates with distinct genotypic and phenotypic profiles under exposure to human plasma proteins.
methodsSixty clinical C. striatum isolates were collected from inpatients at the Affiliated Hospital of Inner Mongolia Medical University between December 2013 and August 2022. The isolates, subcultured onto blood agar plates and the single colonies, were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and antimicrobial susceptibility testing was conducted using the microbroth dilution method. Whole-genome sequencing was performed to assess genetic relatedness and to identify virulence and antibiotic resistance genes. Biofilm formation was evaluated using Congo red agar and crystal violet assays in the presence or absence of fibronectin or fibrinogen.
resultsPhylogenomic analysis classified the 60 C. striatum isolates into five evolutionary clades (I–V), with Clade I as the dominant lineage (45%, 27/60). Biofilm assays showed that 95% (57/60) of C. striatum isolates were biofilm producers, of which 56.14% (32/57) were moderate or strong producers. Notably, 92.59% (25/27) of Clade I isolates exhibited moderate or strong biofilm formation. Multidrug resistance was observed in 95% (57/60) of isolates, with high resistance rates to ciprofloxacin, cefepime, and ceftriaxone. Virulence gene distribution varied significantly across clades, with spaDEF (96.30%) and whiB3 (100%) being highly prevalent in Clade I. Proteinase K showed the strongest biofilm-degrading activity. Exposure to fibronectin or fibrinogen (50 µg/mL) enhanced biofilm formation in 47.37% (27/57) of isolates, whereas biofilm density decreased significantly in most strong biofilm-producing Clade I isolates.
conclusionsThis study reveals significant genomic heterogeneity among C. striatum clinical isolates and their association with biofilm formation. Importantly, it demonstrates isolate- and genotype-dependent effects of human plasma proteins on C. striatum biofilm production, highlighting the potential roles of spaDEF and whiB3 in pathogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.